History
Insulin lispro (brand name Humalog) was granted marketing authorization in the European Union in April 1996, and it was approved for use in the United States in June 1996.Insulin lispro (brand name Liprolog) was granted marketing authorization in the European Union in May 1997, and again in August 2001.Combination drugs combining insulin lispro and other forms of insulin were approved for use in the United States in December 1999.Insulin lispro Sanofi was granted marketing authorization as a biosimilar in the European Union in July 2017.Insulin lispro injection (brand name Admelog) was approved for use in the United States in December 2017.In January 2020, the Committee for Medicinal Products for Human Use (CHMP) in the European Union recommended granting of a marketing authorization for insulin lispro acid (brand name Lyumjev) for the treatment of diabetes mellitus in adults. Insulin lispro (Lyumjev) was approved for use in the European Union in March 2020, and in the United States on 18 June 2020 as reported by Medscape. References
External links
"Insulin lispro". Drug Information Portal. U.S. National Library of Medicine.
Chemotherapy is broken down into 2 phases:

Induction therapy: first short and invasive phase of treatment with the goal to the blood of blasts and reduce the number of blasts in the bone marrow back to normal. Consolidation therapy: second phase given in cycles that occur after the patient has recovered from induction therapy. Its objective is to kill remaining blasts that cant be seen.In some cases, an allogenic bone marrow transplantation can be performed. If AML with chromosomal abnormalities such as inv(16) are often cured by the standard chemotherapy regimen. Prognosis
With AMML being difficult to fully treat, the five-year survival rate is about 38-72% which typically decrease to 35-60% if theres no bone marrow transplantation performed. Generally older patients over 60 have a poor outlook due to prior health status before the diagnosis and the aggressive chemotherapy regimen used. The aggressive chemotherapy regimen can lead to long-term side effects such as prolonged anemia, leukocytopenia, neutropenia, and thrombocytopenia. The use of anthracycline drugs can cause a decrease in cardiac contractility, both short and long term. Those with AML-M4 inv(16) have a favorable prognosis with a five-year overall survival rate of 61%. Epidemiology
AML is commonly seen in pediatric patients with higher pediatric incidence in Hispanics and Asians as compared to non-Hispanic Caucasian and African Americans in the USA. Predisposition to AML includes but not limited to:Down syndrome, Klinefelters syndrome, and Fanconis anemia. Acquired predisposing factors include: aplastic anemia, chemotherapy, prenatal exposure to tobacco, marihuana, and alcohol.